Press Release

Monaco, Principality of Monaco. ONA Therapeutics nominated finalist at Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 14, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce the 11 Patient Entrepreneurs chosen as finalists for the Lyfebulb-Helsinn Cancer Innovation Summit & Award to be held on January 30, 2020. The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of cancer. Valerie Vanhooren, Co-founder and CEO of ONA Therapeutics has been selected as one of the finalists.

Read full press release here:

https://www.helsinn.com/news-and-events/lyfebulb-and-helsinn-announce-11-finalists-for-the-third-annual-lyfebulb-helsinn-cancer-innovation-summit-and-award/

Ona Therapeutics
Privacy Overview
ONA THERAPEUTICS, SL obtains personal data through the contact forms of the web, from those who submit any questions, requests and / or comments.
In accordance with current regulations on Data Protection, specifically, Regulation (EU) 2016/679 of the European Parliament and of the Council, of April 27, 2016, personal data provided to ONA THERAPEUTICS, SL through this web portal will become part of its information systems that comply with the security measures required in order to guarantee the confidentiality, integrity, security and information retrieval.
The purposes for which these data are collected are those of being able to respond to your queries regarding the services we offer. In addition, of the timely response to your queries, we may, if you authorize us to do so, send you information electronically.
Your data will be kept for the period that you are registered to receive the requested information, being your revocable consent, it may be withdrawn at any time through the link that accompanies each shipment to communicate your WITHDRAWN or through an email to the address info@ona-therapeutics.com. From that moment, you will no longer receive any communication from us.
We will not proceed with the communication or transfer of your data, in any case, unless a public body requires it in accordance with the Law and those in charge of treatment that provide services related to our information systems.
You have the right to obtain confirmation about whether we are treating your personal data, therefore, you have the right to access your personal data (Right of Access), you have the right to rectify inaccurate data (Right of Rectification) or to request its deletion (Right to deletion) when the data is no longer necessary, you have the right to exercise your opposition to the processing of data (Right of opposition), to exercise your right to the limitation of the processing, as well as you will have the right to the portability of your data, if it is the case. All this by writing to our access addresses in Calle Baldiri Reixach 10, Barcelona, ​​Spain or via email info@ona-therapeutics.com in accordance with the procedure of articles 15 to 23 of Regulation (EU) 2016 / 679 of the European Parliament and of the Council, of April 27, 2016.
ONA THERAPEUTICS, SL, declares to have implemented the necessary technical and organizational security measures that guarantee the security of the data and prevent its alteration, loss, treatment or unauthorized access, taking into account the state of the technology, the nature of the stored data and the risks to which they are exposed, already come from human action or from the physical or natural environment.
To protect the privacy of the USERS, it is prohibited to send any information regarding their ideology, religion, beliefs, racial origin, health, and sexual life through our forms.
Likewise, we inform you that, under no circumstances will automated individual decisions or profiling be made.